Healthcare · Theme
Eli Lilly blows past estimates, hikes sales outlook on resilient Zepbound and Mounjaro demand

+100
+50
0
−50
−100
Bullish
Bearish
Sun 25
Mon 26
Tue 27
Wed 28
Thu 29
Fri 30
Today
| Day | Score |
|---|---|
| Sun 25 | −57.2 |
| Mon 26 | +17.4 |
| Tue 27 | +60.0 |
| Wed 28 | −2.0 |
| Thu 29 | +56.9 |
| Fri 30 | +4.8 |
| Today | no data |
What this theme is about
Eli Lilly reported that sales of obesity drug Zepbound and diabetes treatment Mounjaro surged again in the third quarter.
Summary drawn from the reporting itself by the Glideslope engine. No AI writing.
- Mood now
- +66.0
- Latest day
- +5
- Stories
- 3
- Sources
- 3


